RVTY — Revvity, Inc.

Summary of Revvity (RVTY) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: $699 million, reflecting 1% organic growth, with foreign exchange (FX) providing a slight 1% tailwind.
• Adjusted Operating Margin: 26.1%, slightly above expectations but down 220 basis points year-over-year due to tariffs, FX, and lower volume leverage.
• Adjusted Earnings Per Share (EPS): $1.18, exceeding guidance by $0.05.
• Free Cash Flow: $120 million, representing approximately 90% of adjusted net income.
• Share Repurchase: $205 million spent on buybacks, totaling $650 million year-to-date, with a new $1 billion repurchase authorization in place.

2. Strategic Updates and Business Highlights

• Business Segments:
  • Signals Software: Grew 20% organically, with strong SaaS performance.
  • Reproductive Health: Mid-single-digit growth, driven by newborn screening.
• New Products: Launched several AI-driven solutions, including the neo LSD seven plex kit, awaiting FDA clearance.
• Partnerships: Collaborations with Genomics England and Sanofi are progressing, with significant potential impacts on diagnostics.
• Sustainability: Achieved a 6% reduction in emissions and received a triple-A ESG rating from MSCI.

3. Forward Guidance and Outlook

• Full-Year Organic Growth: Reiterated guidance of 2% to 4%, with adjusted EPS now expected in the range of $4.90 to $5.00.
• 2026 Outlook: Anticipated organic growth of 2% to 3% and a baseline adjusted operating margin of 28%. Confidence in improved customer activity levels is noted.

4. Bad News, Challenges, or Points of Concern

• China Market: Diagnostics business in China continues to face significant headwinds, with declines in the mid-teens expected to persist into 2026.
• Margins: Year-over-year margin decline attributed to tariffs and lower volume leverage, particularly in the Diagnostics segment.
• Academic and Government Sales: Down mid-single digits, with potential impacts from a government shutdown affecting future performance.

5. Notable Q&A Insights

• Customer Activity: Increasing signs of activity noted primarily in the pharma and biotech sectors, with less engagement from academic and government customers.
• Reagents Performance: Slight decline in reagents attributed to lighter summer months; expectations for continued modest growth.
• Future Instrument Demand: Initial uptick in demand expected for cellular imaging and high content screening instruments.
• Tax Rate: A new baseline tax rate of 18% for 2026 is anticipated, with potential for further leverage.
• M&A Strategy: Focus remains on disciplined capital deployment, prioritizing share buybacks over acquisitions in the current environment.

Overall, Revvity demonstrated solid performance in Q3 2025, with strong cash flow generation and strategic advancements, although challenges in the Chinese market and margin pressures remain points of concern. The company maintains a cautiously optimistic outlook for the remainder of the year and into 2026.